PF-07263689
AXP000105.1 · Oncolytic virus
- Platform
- vaccinia virus
- Originator
- Ignite Immunotherapy
- Sponsor
- Pfizer
Names
| Name | Type | Source |
|---|---|---|
| PF-07263689 | preferred name, code | curator, ncit |
Virus
- Role
- Oncolytic
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Replication
- conditionally replicating
- Modifications
- not disclosed
- Source
- evidence
Cross-references
- NCI Thesaurus
- C183114
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Terminated | Phase 1 | 2021-10-20 | 2022-10-14 | 13 | Bladder Cancer; Colorectal Cancer; Head and Neck Cancer; Hepatocellular Cancer; Melanoma; Non-Small-Cell Lung Cancer; Ovarian Cancer; Renal Cell Cancer; Sarcoma; Squamous Cell Carcinoma |
Recent changes
No changes recorded in its trials yet.
Notes
Oncolytic vaccinia from the Pfizer/Ignite collaboration; phase 1 with sasanlimab (NCT05061537) terminated October 2022. Construct and route not disclosed.
How to cite
PF-07263689 (AXP000105.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000105.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.